AlphAIalphai — Financial news for AI agents
rttnews.comSEP 32 min read$MIST

Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT

Milestone Pharmaceuticals (MIST) received NMPA approval for its Etripamil nasal spray to treat PSVT in China. The approval, based on Phase 3 study data, is the first outside the U.S. and could yield up to $98M in milestones. MIST stock is up 5% at $1.23.

Original reporting
rttnews.com
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT — source image
Source · rttnews.com
Decision brief

The 30-second read

$MISTBullishHigh
01

Why it matters

The approval unlocks a large patient population in China and triggers up‑to $98 million in milestone payments, likely supporting near‑term share price appreciation.

02

Market read

Regulatory approval is a catalyst for Milestone and may influence other cardiac‑therapy biotech stocks.

03

What to watch

Potential reimbursement challenges in China and the need for further data to support broader adoption.

Relevance 9/10Novelty 9/10Timing: today

Background

Milestone Pharmaceuticals (NASDAQ:MIST) announced its first non‑US regulatory clearance for the Etripamil nasal spray, targeting paroxysmal supraventricular tachycardia.

Company-level read

Ticker impact

$MISTBullishHigh confidence
Context

Milestone Pharmaceuticals received NMPA approval for its Etripamil nasal spray, the first regulatory clearance outside the United States.

Expected impact

Potential upside as the stock may rally on the approval and upcoming commercial launch.

Evidence & confidence

Approval is a primary, material event for a biotech; the company also announced up‑to $98 million in milestone payments, which can materially boost cash flow.

Market effects

Sector

Adds a new approved therapy to the cardiac arrhythmia space, potentially pressuring peers without Chinese approvals.

Regional

Strengthens the biotech segment in Greater China and may boost related Chinese pharma stocks.

Global

Demonstrates successful US‑China regulatory navigation, relevant for other US‑listed biotech firms seeking foreign approvals.

Counterpoint

What could challenge this read

The market may have already priced in the approval; execution risk in China could limit upside.

Key entities

  • company
    Milestone Pharmaceuticals Inc.

    US‑listed biotech developing Etripamil.

  • partner
    Everest Medicines

    Exclusive licensee for commercialization in Greater China.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 3
$MISTHighAI 8/10

Milestone Gets China Approval For Etripamil Nasal Spray

Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.

rttnews.com2 min
AUG 21
$MISTMed

Milestone Pharmaceuticals stock gains on Phase 3 AFib trial

Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor

investing.com2 min
AUG 19
$MISTMed

Milestone (MIST) Q2 2026 Earnings Call Transcript

Milestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.

fool.com3 min
AUG 13
$MISTMed

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.

yahoo.com6 min
AUG 12
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

finanznachrichten.de7 min